Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aethlon Medical, Inc. (AEMD)
USD0.69
+0.01 (+0.77%)
US NASDAQ Healthcare Medical - Devices
Address
11555 Sorrento Valley Road 92121
San Diego, CA, US
San Diego, CA, US
CEO
James Frakes
Website
aethlonmedical.com
IPO
1999-03-04
CIK 882291 ISIN US00808Y6041
Description
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.69
+0.01 (+0.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
631.3K
Beta
1.32
Free Float %
0.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.32% | +6.32% | -5.61% | +3.59% | -40.59% | -27.08% | -88.78% | -99.26% | -99.96% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.69
DCF (Unlevered)
6.44
+832.8%
DCF (Levered)
6.96
+908.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-41.04
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+87.6% ★ Q1'26: +97.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%-3,631.5% Q1'26: -3,926.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+331.8% Q1'26: +906.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.05× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 EPS Ana. |
Mar 2028 1 EPS Ana. |
Mar 2029 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
762.4K
est: 3.20M (-76.2%)
|
886.6K
est: 1.50M (-40.9%)
|
392.1K
est: 7.00M (-94.4%)
|
149.6K
est: 75.0K (+99.5%)
|
229.6K
est: 199.8K (+14.9%)
|
650.2K
est: 731.0K (-11.1%)
|
659.1K
est: 990.0K (-33.4%)
|
294.2K
est: 1.01M (-70.8%)
|
574.2K
est: 574.2K (+0.0%)
|
—
est: 1.60M (-100.0%)
|
125.50M
125.50M – 125.50M
+7,743.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
8.87M
8.87M – 8.87M
|
24.03M
24.03M – 24.03M
+170.8% YoY
|
| EBITDA |
-6.50M
est: -640.0K (-915.9%)
|
-4.35M
est: -300.0K (-1,348.7%)
|
-6.97M
est: -1.40M (-397.9%)
|
-5.30M
est: -15.0K (-35,255.7%)
|
-5.97M
est: -40.0K (-14,835.3%)
|
-5.90M
est: -146.2K (-3,938.1%)
|
-7.85M
est: -198.0K (-3,865.5%)
|
-10.30M
est: -201.6K (-5,006.6%)
|
-11.79M
est: -114.8K (-10,164.8%)
|
-13.04M
est: 320.0K (-4,174.5%)
|
25.10M
25.10M – 25.10M
+7,743.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
1.77M
1.77M – 1.77M
|
4.81M
4.81M – 4.81M
+170.8% YoY
|
| EBIT |
-6.54M
est: -640.0K (-921.8%)
|
-4.39M
est: -300.0K (-1,361.7%)
|
-7.00M
est: -1.40M (-400.1%)
|
-5.34M
est: -15.0K (-35,489.0%)
|
-6.00M
est: -40.0K (-14,912.9%)
|
-5.93M
est: -146.2K (-3,956.1%)
|
-7.89M
est: -198.0K (-3,885.6%)
|
-10.42M
est: -201.6K (-5,067.9%)
|
-12.03M
est: -114.8K (-10,374.5%)
|
-13.38M
est: 320.0K (-4,280.6%)
|
25.10M
25.10M – 25.10M
+7,743.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
1.77M
1.77M – 1.77M
|
4.81M
4.81M – 4.81M
+170.8% YoY
|
| Net Income |
-6.80M
est: -16.86M (+59.7%)
|
-4.87M
est: -936.51M (+99.5%)
|
-7.28M
est: 168.57M (-104.3%)
|
-5.68M
est: -899.05M (+99.4%)
|
-6.20M
est: -627.46M (+99.0%)
|
-6.37M
est: -420.80M (+98.5%)
|
-7.89M
est: -85.22M (+90.7%)
|
-10.42M
est: -74.50M (+86.0%)
|
-12.03M
est: -78.67M (+84.7%)
|
-13.39M
est: -39.27M (+65.9%)
|
-6.88M
-6.88M – -6.88M
+82.5% YoY
|
-2.01M
-2.01M – -2.01M
+70.8% YoY
|
-1.21M
-1.21M – -1.21M
+39.7% YoY
|
-411.1K
-411.1K – -411.1K
+66.1% YoY
|
-202.2K
-202.2K – -202.2K
+50.8% YoY
|
-53.9K
-53.9K – -53.9K
+73.3% YoY
|
| SGA |
4.76M
est: 46.80M (-89.8%)
|
5.27M
est: 21.94M (-76.0%)
|
6.49M
est: 102.37M (-93.7%)
|
4.98M
est: 1.10M (+354.1%)
|
6.23M
est: 2.92M (+113.2%)
|
6.58M
est: 10.69M (-38.4%)
|
8.55M
est: 14.48M (-40.9%)
|
10.72M
est: 14.74M (-27.3%)
|
12.47M
est: 8.40M (+48.5%)
|
9.34M
est: 19.57M (-52.3%)
|
1.53B
1.53B – 1.53B
+7,743.8% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
108.52M
108.52M – 108.52M
|
293.92M
293.92M – 293.92M
+170.8% YoY
|
| EPS |
-1,822.50
est: -108.00 (-1,587.5%)
|
-988.50
est: -6,000.00 (+83.5%)
|
-1,405.70
est: 1,080.00 (-230.2%)
|
-691.70
est: -5,760.00 (+88.0%)
|
-513.00
est: -4,020.00 (+87.2%)
|
-186.70
est: -2,696.00 (+93.1%)
|
-65.20
est: -546.00 (+88.1%)
|
-70.60
est: -477.33 (+85.2%)
|
-58.60
est: -504.00 (+88.4%)
|
-85.80
est: -58.27 (-47.3%)
|
-10.21
-10.21 – -10.21
+82.5% YoY
|
-2.99
-2.99 – -2.99
+70.8% YoY
|
-1.80
-1.80 – -1.80
+39.7% YoY
|
-0.61
-0.61 – -0.61
+66.1% YoY
|
-0.30
-0.30 – -0.30
+50.8% YoY
|
-0.08
-0.08 – -0.08
+73.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-10 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-06-09 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-03 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-02 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-06-01 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.72B
OE per share TTM
-8,276.31
Owner's Yield
-54,223.72%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
295.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
155.0K
Insider transactions (90d)
4
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sachs Investment Group, LLC | 1.91M | 11.50% | — | — | 1.91M | — | IA | United States | 2018-02-13 | ↗ |
| 2 | Armistice Capital Master Fund Ltd. | 315.6K | 3.80% | — | 315.6K | — | 315.6K | CO | Delaware | 2020-01-24 | ↗ |
| 3 | Armistice Capital, LLC | 315.6K | 3.80% | — | 315.6K | — | 315.6K | IA, OO | Delaware | 2020-01-24 | ↗ |
| 4 | Steven Boyd | 315.6K | 3.80% | — | 315.6K | — | 315.6K | HC, IN | Delaware | 2020-01-24 | ↗ |
| 5 | Daniel B. Asher | 179.1K | 1.50% | — | 179.1K | — | 179.1K | HC, IN | United States of America | 2021-01-29 | ↗ |
| 6 | Intracoastal Capital LLC | 179.1K | 1.50% | — | 179.1K | — | 179.1K | OO | United States of America | 2021-01-29 | ↗ |
| 7 | Mitchell P. Kopin | 179.1K | 1.50% | — | 179.1K | — | 179.1K | HC, IN | United States of America | 2021-01-29 | ↗ |
| 8 | Richard Abbe | 149.2K | 1.22% | 44.6K | 104.6K | 44.6K | 104.6K | HC, IN | Delaware | 2021-02-22 | ↗ |
| 9 | Empery Asset Management, LP | 105.0K | 0.68% | — | 105.0K | — | — | PN | Delaware | 2022-01-13 | ↗ |
| 10 | Martin D. Hoe | 105.0K | 0.68% | — | 105.0K | — | — | IN | Delaware | 2022-01-13 | ↗ |
| 11 | Ryan M. Lane | 105.0K | 0.68% | — | 105.0K | — | — | IN | Delaware | 2022-01-13 | ↗ |
| 12 | Iroquois Capital Management L.L.C. | 104.6K | 0.86% | — | 104.6K | — | 104.6K | OO | Delaware | 2021-02-22 | ↗ |
| 13 | Kimberly Page | 104.6K | 0.85% | — | 104.6K | — | 104.6K | IN | Delaware | 2021-02-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
+4 vs prev Q
New positions
6
Closed positions
2
Increased
6
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | IKARIAN CAPITAL, LLC | 14.4K +14.4K (+100.0%) | 39.8K +39.8K (+100.0%) | 1.75% +1.745 pp | 0.00% +0.003 pp | USD2.77 +0.0% | 1 qtrs NEW |
| 2 | MORGAN STANLEY | 2.0K +2.0K (+100.0%) | 5.7K +5.7K (+100.0%) | 0.25% +0.249 pp | 0.00% +0.000 pp | USD2.77 +0.0% | 1 qtrs NEW |
| 3 | CITIGROUP INC | 33.00 +33.0 (+100.0%) | 91.00 +91.0 (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD2.76 +0.4% | 1 qtrs NEW |
| 4 | GROUP ONE TRADING, L.P. | 14.00 +14.0 (+100.0%) | 39.00 +39.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.71 +2.2% | 1 qtrs NEW |
| 5 | BLACKROCK, INC. | 10.00 +10.0 (+100.0%) | 28.00 +28.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.70 +2.6% | 1 qtrs NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 6.00 +6.0 (+100.0%) | 17.00 +17.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD2.67 +3.7% | 1 qtrs NEW |
| 7 | WELLS FARGO & COMPANY/MN | 3.00 +3.0 (+100.0%) | 7.00 +7.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.67 +3.7% | 1 qtrs NEW |
| 8 | DANSKE BANK A/S | 1.00 +1.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +38.5% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
3
Shares acquired
—
Shares disposed
445.00
Cash buys
—
Cash sales
—
Net activity
-445
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Shah Chetan | Director | A-Award | A | Common Stock | 21,815 | 2.29 | 50.0K | 23,021 | D | ↗ |
| 2026-04-17 | Rossetti Angela | Director | A-Award | A | Common Stock | 21,815 | 2.29 | 50.0K | 26,207 | D | ↗ |
| 2026-04-17 | Gikakis Nicolas | Director | A-Award | A | Common Stock | 21,815 | 2.29 | 50.0K | 22,844 | D | ↗ |
| 2026-04-17 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 21,815 | 2.29 | 50.0K | 23,454 | D | ↗ |
| 2026-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 178 | 2.19 | 389.82 | 1,463 | D | ↗ |
| 2026-03-31 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 178 | 2.19 | 389.82 | 1,464 | D | ↗ |
| 2026-03-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 89 | 2.19 | 194.91 | 1,915 | D | ↗ |
| 2025-12-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 179 | 2.77 | 495.83 | 2,356 | D | ↗ |
| 2025-12-31 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 179 | 2.77 | 495.83 | 2,357 | D | ↗ |
| 2025-12-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 89 | 2.77 | 246.53 | 2,807 | D | ↗ |
| 2025-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 1,786 | 0.75 | 1.3K | 22,672 | D | ↗ |
| 2025-09-30 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 1,786 | 0.75 | 1.3K | 22,683 | D | ↗ |
| 2025-09-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 893 | 0.75 | 668.86 | 25,397 | D | ↗ |
| 2025-06-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 1,786 | 1.20 | 2.1K | 19,993 | D | ↗ |
| 2025-06-30 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 1,786 | 1.20 | 2.1K | 20,004 | D | ↗ |
| 2025-06-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 893 | 1.20 | 1.1K | 21,825 | D | ↗ |
| 2025-04-23 | Shah Chetan | Director | A-Award | D | Common Stock | 142,857 | 0.36 | 51.1K | 174,233 | D | ↗ |
| 2025-04-23 | Rossetti Angela | Director | A-Award | A | Common Stock | 142,857 | 0.35 | 50.0K | 343,400 | D | ↗ |
| 2025-04-23 | Gikakis Nicolas | Director | A-Award | A | Common Stock | 142,857 | 0.35 | 50.0K | 174,320 | D | ↗ |
| 2025-04-23 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 142,857 | 0.35 | 50.0K | 181,741 | D | ↗ |
| 2025-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,289 | 0.36 | 1.2K | 31,376 | D | ↗ |
| 2025-03-31 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 3,289 | 0.36 | 1.2K | 31,463 | D | ↗ |
| 2025-03-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,645 | 0.36 | 588.91 | 38,884 | D | ↗ |
| 2024-12-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,289 | 0.86 | 2.8K | 34,665 | D | ↗ |
| 2024-12-31 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 3,289 | 0.86 | 2.8K | 34,752 | D | ↗ |
| 2024-12-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,645 | 0.86 | 1.4K | 40,529 | D | ↗ |
| 2024-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,289 | 0.47 | 1.5K | 37,954 | D | ↗ |
| 2024-09-30 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 3,289 | 0.47 | 1.5K | 38,041 | D | ↗ |
| 2024-09-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,645 | 0.47 | 766.57 | 42,174 | D | ↗ |
| 2024-06-28 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,289 | 0.50 | 1.6K | 41,243 | — | ↗ |
| 2024-06-28 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 5,244 | 0.50 | 2.6K | 41,330 | — | ↗ |
| 2024-06-28 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,645 | 0.50 | 820.86 | 43,819 | — | ↗ |
| 2024-04-16 | Shah Chetan | Director | A-Award | A | Common Stock | 32,894 | 1.52 | 50.0K | 44,532 | — | ↗ |
| 2024-04-16 | Rossetti Angela | Director | A-Award | A | Common Stock | 32,894 | 1.52 | 50.0K | 200,543 | — | ↗ |
| 2024-04-16 | Gikakis Nicolas | Director | A-Award | A | Common Stock | 32,894 | 1.52 | 50.0K | 46,574 | — | ↗ |
| 2024-04-16 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 32,894 | 1.52 | 50.0K | 45,464 | — | ↗ |
| 2024-03-29 | Shah Chetan | Director | F-InKind | D | Common Stock | 1,163 | 1.68 | 2.0K | 11,638 | — | ↗ |
| 2024-03-29 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 1,954 | 1.68 | 3.3K | 13,680 | — | ↗ |
| 2024-03-29 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,163 | 1.68 | 2.0K | 12,570 | — | ↗ |
| 2023-12-29 | Shah Chetan | Director | F-InKind | D | Common Stock | 1,163 | 2.19 | 2.5K | 12,801 | — | ↗ |
| 2023-12-29 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 1,954 | 2.19 | 4.3K | 15,634 | — | ↗ |
| 2023-12-29 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 1,163 | 2.19 | 2.5K | 13,733 | — | ↗ |
| 2023-09-29 | Shah Chetan | Director | F-InKind | D | Common Stock | 11,628 | 0.23 | 2.7K | 139,637 | — | ↗ |
| 2023-09-29 | Gikakis Nicolas | Director | F-InKind | D | Common Stock | 19,541 | 0.23 | 4.5K | 175,873 | — | ↗ |
| 2023-09-29 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 11,628 | 0.23 | 2.7K | 148,957 | — | ↗ |
| 2023-07-03 | Gikakis Nicolas | Director | A-Award | A | Common Stock | 195,414 | 0.00 | — | 195,414 | — | ↗ |
| 2023-06-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 11,628 | 0.36 | 4.2K | 151,265 | — | ↗ |
| 2023-06-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 11,628 | 0.36 | 4.2K | 160,585 | — | ↗ |
| 2023-04-28 | Shah Chetan | Director | A-Award | A | Common Stock | 116,279 | 0.00 | — | 162,893 | — | ↗ |
| 2023-04-28 | Rossetti Angela | Director | A-Award | A | Common Stock | 116,279 | 0.00 | — | 167,649 | — | ↗ |
| 2023-04-28 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 116,279 | 0.00 | — | 172,213 | — | ↗ |
| 2023-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,425 | 0.39 | 1.3K | 46,614 | — | ↗ |
| 2023-03-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 3,425 | 0.39 | 1.3K | 55,934 | — | ↗ |
| 2023-02-01 | Arnold Lee D | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,620 | 0.69 | 41.8K | 60,620 | — | ↗ |
| 2022-12-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,425 | 0.28 | 941.88 | 50,039 | — | ↗ |
| 2022-12-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 3,425 | 0.28 | 941.88 | 59,359 | — | ↗ |
| 2022-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 6,849 | 0.58 | 4.0K | 53,464 | — | ↗ |
| 2022-09-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 6,849 | 0.58 | 4.0K | 62,784 | — | ↗ |
| 2022-09-15 | Shah Chetan | Director | A-Award | A | Common Stock | 34,247 | 0.00 | — | 60,313 | — | ↗ |
| 2022-09-15 | Rossetti Angela | Director | A-Award | A | Common Stock | 51,370 | 0.00 | — | 51,370 | — | ↗ |
| 2022-09-15 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 34,247 | 0.00 | — | 69,633 | — | ↗ |
| 2022-04-01 | Rossetti Angela | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,430 | 1.46 | 3.5K | 26,066 | — | ↗ |
| 2022-03-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,430 | 1.46 | 3.5K | 33,642 | — | ↗ |
| 2022-03-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,430 | 1.46 | 3.5K | 35,386 | — | ↗ |
| 2022-02-10 | LAROSA STEVEN P | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,200 | 1.41 | 141.3K | 100,200 | — | ↗ |
| 2022-02-10 | FRAKES JAMES B | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,200 | 1.41 | 141.3K | 100,200 | — | ↗ |
| 2022-02-10 | FISHER CHARLES J JR | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 192,600 | 0.00 | — | 192,600 | — | ↗ |
| 2022-02-10 | Cipriani Guy F. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,200 | 1.41 | 141.3K | 100,200 | — | ↗ |
| 2021-12-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,430 | 1.86 | 4.5K | 28,496 | — | ↗ |
| 2021-12-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,430 | 1.86 | 4.5K | 36,072 | — | ↗ |
| 2021-12-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,430 | 1.86 | 4.5K | 37,816 | — | ↗ |
| 2021-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,430 | 3.86 | 9.4K | 30,926 | — | ↗ |
| 2021-09-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,430 | 3.86 | 9.4K | 38,502 | — | ↗ |
| 2021-09-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,430 | 3.86 | 9.4K | 40,246 | — | ↗ |
| 2021-06-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,430 | 4.91 | 11.9K | 33,356 | — | ↗ |
| 2021-06-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,430 | 4.91 | 11.9K | 40,932 | — | ↗ |
| 2021-06-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,430 | 4.91 | 11.9K | 42,676 | — | ↗ |
| 2021-06-28 | FISHER CHARLES J JR | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 266,888 | 5.17 | 1.38M | 266,888 | — | ↗ |
| 2021-04-01 | Shah Chetan | Director | A-Award | A | Common Stock | 24,295 | 2.06 | 50.0K | 35,786 | — | ↗ |
| 2021-04-01 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Common Stock | 24,295 | 2.06 | 50.0K | 43,362 | — | ↗ |
| 2021-04-01 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 24,295 | 2.06 | 50.0K | 45,106 | — | ↗ |
| 2021-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,575 | 2.03 | 5.2K | 11,491 | — | ↗ |
| 2021-03-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,575 | 2.03 | 5.2K | 19,067 | — | ↗ |
| 2021-03-31 | FISHER CHARLES J JR | Director / Officer | F-InKind | D | Common Stock | 2,575 | 2.03 | 5.2K | 19,569 | — | ↗ |
| 2021-03-31 | Cipriani Guy F. | Director / Officer | F-InKind | D | Common Stock | 2,575 | 2.03 | 5.2K | 17,901 | — | ↗ |
| 2021-03-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,575 | 2.03 | 5.2K | 20,811 | — | ↗ |
| 2021-01-04 | LAROSA STEVEN P | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,883 | 2.52 | 304.6K | 120,883 | — | ↗ |
| 2021-01-04 | Cipriani Guy F. | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,883 | 2.52 | 304.6K | 120,883 | — | ↗ |
| 2020-12-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,575 | 2.47 | 6.4K | 14,066 | — | ↗ |
| 2020-12-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,575 | 2.47 | 6.4K | 21,642 | — | ↗ |
| 2020-12-31 | FISHER CHARLES J JR | Director / Officer | F-InKind | D | Common Stock | 2,575 | 2.47 | 6.4K | 22,144 | — | ↗ |
| 2020-12-31 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 2,575 | 2.47 | 6.4K | 20,476 | — | ↗ |
| 2020-12-31 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,575 | 2.47 | 6.4K | 23,386 | — | ↗ |
| 2020-12-17 | Shah Chetan | Director | S-Sale | D | Common Stock | 21,101 | 2.11 | 44.5K | 22,392 | — | ↗ |
| 2020-10-30 | FISHER CHARLES J JR | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 239,122 | 1.34 | 320.4K | 239,122 | — | ↗ |
| 2020-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,389 | 1.35 | 3.2K | 43,493 | — | ↗ |
| 2020-09-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,389 | 1.35 | 3.2K | 24,217 | — | ↗ |
| 2020-09-30 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 2,389 | 1.35 | 3.2K | 24,719 | — | ↗ |
| 2020-09-30 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 2,389 | 1.35 | 3.2K | 23,051 | — | ↗ |
| 2020-09-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,389 | 1.35 | 3.2K | 25,961 | — | ↗ |
| 2020-06-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 2,389 | 2.03 | 4.8K | 44,953 | — | ↗ |
| 2020-06-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 2,389 | 2.03 | 4.8K | 25,677 | — | ↗ |
| 2020-06-30 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 2,389 | 2.03 | 4.8K | 26,179 | — | ↗ |
| 2020-06-30 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 2,389 | 2.03 | 4.8K | 24,511 | — | ↗ |
| 2020-06-30 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 2,389 | 2.03 | 4.8K | 27,421 | — | ↗ |
| 2020-04-03 | Shah Chetan | Director | A-Award | A | Common Stock | 929 | 0.00 | — | 45,882 | — | ↗ |
| 2020-04-03 | RODELL TIMOTHY C JR | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 202,280 | 1.28 | 258.9K | 202,280 | — | ↗ |
| 2020-04-03 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Common Stock | 929 | 0.00 | — | 26,606 | — | ↗ |
| 2020-04-03 | FRAKES JAMES B | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,472 | 1.28 | 179.8K | 140,472 | — | ↗ |
| 2020-04-03 | FISHER CHARLES J JR | Director | A-Award | A | Common Stock | 929 | 0.00 | — | 27,108 | — | ↗ |
| 2020-04-03 | Cipriani Guy F. | Director | A-Award | A | Common Stock | 929 | 0.00 | — | 25,440 | — | ↗ |
| 2020-04-03 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 929 | 0.00 | — | 28,350 | — | ↗ |
| 2020-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 244 | 1.52 | 370.88 | 23,449 | — | ↗ |
| 2020-03-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 244 | 1.52 | 370.88 | 4,173 | — | ↗ |
| 2020-03-31 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 244 | 1.52 | 370.88 | 4,675 | — | ↗ |
| 2020-03-31 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 244 | 1.52 | 370.88 | 3,007 | — | ↗ |
| 2020-01-31 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 125 | 3.70 | 462.50 | 2,483 | — | ↗ |
| 2019-12-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 246 | 0.84 | 207.60 | 23,693 | — | ↗ |
| 2019-12-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 246 | 0.84 | 207.60 | 4,417 | — | ↗ |
| 2019-12-31 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 246 | 0.84 | 207.60 | 4,919 | — | ↗ |
| 2019-12-31 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 246 | 0.84 | 207.60 | 3,251 | — | ↗ |
| 2019-10-30 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 115 | 3.93 | 451.95 | 2,608 | — | ↗ |
| 2019-09-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,684 | 0.24 | 865.74 | 359,075 | — | ↗ |
| 2019-09-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 3,684 | 0.24 | 865.74 | 69,944 | — | ↗ |
| 2019-09-30 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 3,684 | 0.24 | 865.74 | 77,469 | — | ↗ |
| 2019-09-30 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 3,684 | 0.24 | 865.74 | 52,444 | — | ↗ |
| 2019-07-31 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 113 | 3.30 | 372.90 | 2,723 | — | ↗ |
| 2019-06-30 | Shah Chetan | Director | F-InKind | D | Common Stock | 3,684 | 0.37 | 1.4K | 362,759 | — | ↗ |
| 2019-06-30 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 3,684 | 0.37 | 1.4K | 73,628 | — | ↗ |
| 2019-06-30 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 3,684 | 0.37 | 1.4K | 81,153 | — | ↗ |
| 2019-06-30 | Cipriani Guy F. | Director | F-InKind | D | Common Stock | 3,684 | 0.37 | 1.4K | 56,128 | — | ↗ |
| 2019-04-30 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 129 | 11.25 | 1.5K | 2,836 | — | ↗ |
| 2019-04-01 | Shah Chetan | Director | A-Award | A | Restricted Stock Units (RSU) | 36,842 | 0.00 | — | 36,842 | — | ↗ |
| 2019-04-01 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Restricted Stock Units (RSU) | 36,842 | 0.00 | — | 36,842 | — | ↗ |
| 2019-04-01 | FISHER CHARLES J JR | Director | A-Award | A | Restricted Stock Units (RSU) | 36,842 | 0.00 | — | 36,842 | — | ↗ |
| 2019-04-01 | Cipriani Guy F. | Director | A-Award | A | Restricted Stock Units (RSU) | 36,842 | 0.00 | — | 36,842 | — | ↗ |
| 2019-04-01 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 36,842 | 0.00 | — | 88,747 | — | ↗ |
| 2019-03-31 | Shah Chetan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-31 | JOHNSON SABRINA MARTUCCI | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-31 | FRAKES JAMES B | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-31 | FISHER CHARLES J JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-31 | Cipriani Guy F. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-10 | RODELL TIMOTHY C JR | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-31 | KENLEY RODNEY S | Director / Officer | C-Conversion | D | Restricted Stock Units | 3,250 | 0.00 | — | 22,435 | — | ↗ |
| 2018-10-31 | Joyce James A | Director / Officer | C-Conversion | D | Restricted Stock Units | 39,625 | 0.00 | — | 279,064 | — | ↗ |
| 2018-10-31 | FRAKES JAMES B | Officer | C-Conversion | D | Restricted Stock Units | 3,250 | 0.00 | — | 46,539 | — | ↗ |
| 2018-09-28 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 4,015 | 1.18 | 4.7K | 56,686 | — | ↗ |
| 2018-07-31 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,797 | 1.23 | 2.2K | 18,590 | — | ↗ |
| 2018-07-31 | Joyce James A | Director / Officer | M-Exempt | A | Common Stock | 18,683 | 1.23 | 23.0K | 193,687 | — | ↗ |
| 2018-07-31 | FRAKES JAMES B | Officer | M-Exempt | A | Common Stock | 1,562 | 1.23 | 1.9K | 16,345 | — | ↗ |
| 2018-06-19 | Shah Chetan | Director | A-Award | A | Restricted Stock Units | 26,799 | 0.00 | — | 80,465 | — | ↗ |
| 2018-06-19 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Restricted Stock Units | 26,799 | 0.00 | — | 67,449 | — | ↗ |
| 2018-06-19 | FRAKES JAMES B | Officer | A-Award | A | Restricted Stock Units | 22,971 | 0.00 | — | 53,039 | — | ↗ |
| 2018-06-19 | FISHER CHARLES J JR | Director | A-Award | A | Restricted Stock Units | 26,799 | 0.00 | — | 79,990 | — | ↗ |
| 2018-06-19 | Cipriani Guy F. | Director | — | D | Restricted Stock Units | 38,285 | 0.00 | — | 0 | — | ↗ |
| 2018-06-19 | BROENNIMAN EDWARD G | Director | A-Award | A | Restricted Stock Units | 26,799 | 0.00 | — | 80,465 | — | ↗ |
| 2018-06-14 | Shah Chetan | Director | A-Award | A | Common Stock | 26,799 | 0.00 | — | 340,320 | — | ↗ |
| 2018-06-14 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Common Stock | 26,799 | 0.00 | — | 51,189 | — | ↗ |
| 2018-06-14 | FRAKES JAMES B | Officer | A-Award | A | Common Stock | 22,971 | 0.00 | — | 62,389 | — | ↗ |
| 2018-06-14 | FISHER CHARLES J JR | Director | A-Award | A | Common Stock | 26,799 | 0.00 | — | 58,714 | — | ↗ |
| 2018-06-14 | Cipriani Guy F. | Director | A-Award | A | Common Stock | 38,285 | 0.00 | — | 38,285 | — | ↗ |
| 2018-06-14 | BROENNIMAN EDWARD G | Director | A-Award | A | Common Stock | 26,799 | 0.00 | — | 79,536 | — | ↗ |
| 2018-04-30 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,596 | 1.34 | 2.1K | 16,793 | — | ↗ |
| 2018-04-30 | Joyce James A | Director / Officer | M-Exempt | A | Common Stock | 18,771 | 1.34 | 25.2K | 175,004 | — | ↗ |
| 2018-04-30 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 1,922 | 1.34 | 2.6K | 39,418 | — | ↗ |
| 2018-03-31 | Shah Chetan | Director | F-InKind | D | Common Stock | 7,447 | 1.19 | 8.9K | 313,521 | — | ↗ |
| 2018-03-31 | JOHNSON SABRINA MARTUCCI | Director | F-InKind | D | Common Stock | 16,260 | 1.19 | 19.3K | 24,390 | — | ↗ |
| 2018-03-31 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 10,638 | 1.19 | 12.7K | 31,915 | — | ↗ |
| 2018-02-15 | JOHNSON SABRINA MARTUCCI | Director | — | D | Restricted Stock Units | 40,650 | 0.00 | — | 0 | — | ↗ |
| 2018-02-06 | JOHNSON SABRINA MARTUCCI | Director | A-Award | A | Common Stock | 40,650 | 0.00 | — | 40,650 | — | ↗ |
| 2018-01-31 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,596 | 1.50 | 2.4K | 15,197 | — | ↗ |
| 2018-01-31 | Joyce James A | Director / Officer | M-Exempt | A | Common Stock | 16,979 | 1.50 | 25.5K | 156,233 | — | ↗ |
| 2018-01-31 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 1,857 | 1.50 | 2.8K | 41,340 | — | ↗ |
| 2017-12-31 | FISHER CHARLES J JR | Director | F-InKind | D | Common Stock | 10,638 | 1.14 | 12.1K | 42,553 | — | ↗ |
| 2017-12-29 | Joyce James A | Director / Officer | G-Gift | D | Common Stock | 16,000 | 0.00 | — | 139,254 | — | ↗ |
| 2017-12-12 | JOHNSON SABRINA MARTUCCI | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-11 | FISHER CHARLES J JR | Director | — | D | Restricted Stock Units | 53,191 | 0.00 | — | 0 | — | ↗ |
| 2017-11-27 | Shah Chetan | Director | A-Award | A | Restricted Stock Units | 37,234 | 0.00 | — | 53,666 | — | ↗ |
| 2017-11-27 | BROENNIMAN EDWARD G | Director | A-Award | A | Restricted Stock Units | 37,234 | 0.00 | — | 53,666 | — | ↗ |
| 2017-10-30 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,768 | 0.98 | 1.7K | 13,601 | — | ↗ |
| 2017-10-30 | Joyce James A | Director / Officer | C-Conversion | D | Restricted Stock Units | 39,625 | 0.00 | — | 437,564 | — | ↗ |
| 2017-10-30 | FRAKES JAMES B | Officer | C-Conversion | D | Restricted Stock Units | 3,250 | 0.00 | — | 36,568 | — | ↗ |
| 2017-10-11 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,768 | 1.14 | 2.0K | 11,833 | — | ↗ |
| 2017-10-11 | Joyce James A | Director / Officer | M-Exempt | A | Common Stock | 19,079 | 1.14 | 21.8K | 136,175 | — | ↗ |
| 2017-10-11 | FRAKES JAMES B | Officer | M-Exempt | A | Common Stock | 1,565 | 1.14 | 1.8K | 10,497 | — | ↗ |
| 2017-09-28 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 1,685 | 1.14 | 1.9K | 43,197 | — | ↗ |
| 2017-05-01 | KENLEY RODNEY S | Director / Officer | M-Exempt | A | Common Stock | 1,797 | 2.23 | 4.0K | 10,065 | — | ↗ |
| 2017-05-01 | Joyce James A | Director / Officer | M-Exempt | A | Common Stock | 19,079 | 2.23 | 42.5K | 117,096 | — | ↗ |
| 2017-05-01 | FRAKES JAMES B | Officer | D-Return | D | Restricted Stock Units | 1,594 | 0.00 | — | 43,068 | — | ↗ |
| 2017-04-30 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 1,656 | 2.23 | 3.7K | 44,882 | — | ↗ |
| 2017-02-07 | KENLEY RODNEY S | Director / Officer | D-Return | D | Restricted Stock Units | 8,268 | 0.00 | — | 43,732 | — | ↗ |
| 2017-02-07 | Joyce James A | Director / Officer | D-Return | D | Restricted Stock Units | 98,107 | 0.00 | — | 535,893 | — | ↗ |
| 2017-02-07 | FRAKES JAMES B | Officer | M-Exempt | A | Common Stock | 7,338 | 4.28 | 31.4K | 7,338 | — | ↗ |
| 2017-01-31 | FRAKES JAMES B | Officer | F-InKind | D | Common Stock | 5,662 | 4.28 | 24.2K | 46,538 | — | ↗ |
| 2016-09-30 | Shah Chetan | Director | M-Exempt | D | Restricted Stock Units | 1,368 | 0.00 | — | 2,736 | — | ↗ |
| 2016-09-30 | BROENNIMAN EDWARD G | Director | M-Exempt | D | Restricted Stock Units | 1,368 | 0.00 | — | 2,736 | — | ↗ |
| 2016-09-30 | BARRY FRANKLYN S JR | Director | M-Exempt | A | Common Stock | 821 | 0.00 | — | 10,340 | — | ↗ |
| 2016-09-01 | Shah Chetan | Director | M-Exempt | D | Restricted Stock Units | 12,328 | 0.00 | — | 4,104 | — | ↗ |
| 2016-09-01 | BROENNIMAN EDWARD G | Director | F-InKind | D | Common Stock | 4,931 | 6.28 | 31.0K | 13,040 | — | ↗ |
Executive team
Top executives
Shares Outstanding
761.3K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | James B. Frakes Chief Executive Officer and Chief Financial Officer | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 2 | 2025 | Steven P. LaRosa, M.D. Chief Medical Officer | 430.0K | — | — | — | — | 50.0K | 480.0K | 0.00% | ↗ |
| 3 | 2025 | Guy F. Cipriani Senior Vice President, Chief Operating Officer | 199.5K | — | — | — | — | 196.2K | 395.7K | 0.00% | ↗ |
| 4 | 2024 | Steven P. LaRosa, M.D. Chief Medical Officer | 430.0K | — | — | — | — | — | 430.0K | 0.00% | ↗ |
| 5 | 2024 | James B. Frakes Chief Executive Officer and Chief Financial Officer | 416.4K | — | — | — | — | — | 416.4K | 0.00% | ↗ |
| 6 | 2024 | Guy F. Cipriani Senior Vice President, Chief Operating Officer | 378.1K | — | — | — | — | — | 378.1K | 0.00% | ↗ |
| 7 | 2022 | Charles J. Fisher, Jr., M.D. CHIEF EXECUTIVE OFFICER | 436.3K | — | — | 1.61M | 430.0K | — | 2.48M | 65.04% | ↗ |
| 8 | 2022 | Steven P. LaRosa, M.D. CHIEF MEDICAL OFFICER and Chief Scientific Officer | 421.1K | — | — | 137.3K | 160.0K | 74.2K | 792.6K | 17.32% | ↗ |
| 9 | 2022 | Guy F. Cipriani Senior Vice President, Chief Business Officer | 340.0K | — | — | 137.3K | 136.0K | 159.6K | 772.9K | 17.76% | ↗ |
| 10 | 2021 | Steven P. LaRosa, M.D. CHIEF MEDICAL OFFICER and Chief Scientific Officer | 100.0K | 100.0K | — | 280.4K | — | — | 480.4K | 58.37% | ↗ |
| 11 | 2021 | Charles J. Fisher, Jr., M.D. CHIEF EXECUTIVE OFFICER | 180.8K | — | — | 294.1K | — | — | 474.9K | 61.93% | ↗ |
| 12 | 2021 | Guy F. Cipriani Senior Vice President, Chief Business Officer | 85.0K | — | — | 280.4K | — | — | 365.4K | 76.74% | ↗ |
| 13 | 2009 | James A. Joyce Chief Executive Officer | 290.0K | — | — | 424.5K | — | — | 714.5K | 59.41% | ↗ |
| 14 | 2009 | Richard H. Tullis, Ph.D Chief Science Officer | 180.0K | — | — | 154.0K | — | — | 334.0K | 46.11% | ↗ |
| 15 | 2008 | James A. Joyce Chief Executive Officer | 256.0K | — | — | — | — | — | 256.0K | 0.00% | ↗ |
| 16 | 2008 | Richard H. Tullis, Ph.D Chief Science Officer | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Frakes | Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Secretary & Director | 500.0K | male |
| Steven LaRosa | Chief Medical Officer | 480.0K | male |
| Michele Bombardiere | Vice President & Controller | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AEMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
